Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

As with any medicinal product, the MHRA will keep the safety and effectiveness of nerandomilast under close review.  

Follow this news feed: